Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell 4.5% during mid-day trading on Wednesday . The company traded as low as $25.95 and last traded at $25.99, with a volume of 788,901 shares trading hands. The stock had previously closed at $27.21.

A number of brokerages have issued reports on SRPT. Cowen and Company restated a “market perform” rating on shares of Sarepta Therapeutics in a research report on Monday, August 15th. Janney Montgomery Scott restated a “neutral” rating and set a $30.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, August 11th. Leerink Swann restated an “underperform” rating and set a $5.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, August 4th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, July 26th. Finally, JMP Securities restated an “underperform” rating and set a $10.00 price objective on shares of Sarepta Therapeutics in a research report on Sunday, July 24th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $24.29.

The firm’s market capitalization is $1.25 billion. The firm has a 50 day moving average price of $24.72 and a 200-day moving average price of $19.60.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period last year, the business posted ($0.87) EPS. Equities analysts expect that Sarepta Therapeutics Inc. will post ($5.16) earnings per share for the current fiscal year.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.